Internal Medicine, Gastroenterology · Simi Valley, CA
NPI
1508965476
Since 2006
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
1159 Roadrunner Way
Simi Valley, CA, 93065
Phone (805) 583-2643
Groups this clinician bills Medicare through
Medicare paid, 2024
$133K
1,509 services
Medicare patients, 2024
665
Average age 74
Drug cost, 2024
$1.5M
3,038 prescriptions
Company payments, 2025
$3,486
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Moe Amadpour was code 99214 (office e&m - established), 532 times for 326 patients. In total Moe Amadpour billed 1,509 services in 27 codes, and Medicare paid $133K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 532 | 326 | $81.06 | $43K |
| 43239 Upper GI Endoscopy | Facility | 174 | 168 | $83.20 | $14K |
| 99223 Hospital E&M - Initial | Facility | 141 | 138 | $117.99 | $17K |
| 99232 Hospital E&M - Subsequent | Facility | 111 | 71 | $55.84 | $6,198 |
| 99204 Office E&M - New | Office | 109 | 109 | $107.30 | $12K |
| 45380 Lower GI Endoscopy - Other | Facility | 109 | 109 | $133.16 | $15K |
| 99203 Office E&M - New | Office | 96 | 96 | $61.63 | $5,917 |
| 99231 Hospital E&M - Subsequent | Facility | 87 | 53 | $35.05 | $3,049 |
| 45378 Lower GI Endoscopy - Other | Facility | 55 | 55 | $120.38 | $6,621 |
| 45385 Colonoscopy - Lesion Removal | Facility | 23 | 23 | $162.93 | $3,747 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 17 | 17 | $165.33 | $2,811 |
| 99213 Office E&M - Established | Office | 17 | 17 | $53.07 | $902 |
By year: 2022 $153K for 1,780 services; 2023 $170K for 1,782 services; 2024 $133K for 1,509 services.
Medicare prescription drug claims, 2024
In 2024, the drug Moe Amadpour prescribed most often to Medicare patients was Pantoprazole Sodium, with 1,063 prescriptions and refills. In total Moe Amadpour wrote 3,038 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Pantoprazole Sodium Generic | 1,063 | 2,487 | 325 | $13K |
| Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates | 209 | 209 | 204 | $12K |
| Dexlansoprazole Dr Dexlansoprazole | 140 | 306 | 43 | $53K |
| Linzess Linaclotide | 125 | 187 | 37 | $99K |
| Famotidine Generic | 93 | 189 | 25 | $606 |
| Sodium Chloride 0.9 % Sodium Chloride | 88 | 88 | Under 11 | $1,286 |
| Metoclopramide Hcl Generic | 80 | 112 | 18 | $474 |
| Voquezna Vonoprazan Fumarate | 71 | 120 | 24 | $73K |
| Omeprazole Generic | 69 | 188 | 25 | $1,105 |
| Ondansetron Hcl Generic | 57 | 65 | 12 | $1,539 |
| Rabeprazole Sodium Generic | 53 | 77 | 23 | $5,005 |
| Lubiprostone Generic | 44 | 58 | 13 | $5,041 |
| Mesalamine Generic | 39 | 85 | 12 | $17K |
| Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl | 37 | 37 | 33 | $357 |
| Xifaxan Rifaximin | 35 | 35 | 12 | $84K |
Brand drugs: - claims; generic drugs: 2,387 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Moe Amadpour $3,486 ($3,486 in general payments such as food, travel and fees) from 17 companies. The largest payer was Janssen Biotech, Inc. with $748.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 10 | $748 |
| Abbvie Inc. ABBV | 20 | $404 |
| Madrigal Pharmaceuticals MDGL | 8 | $396 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 13 | $343 |
| Lilly USA, LLC LLY | 10 | $330 |
| Phathom Pharmaceuticals, Inc. PHAT | 7 | $228 |
| Ardelyx, Inc. ARDX | 10 | $223 |
| Gilead Sciences, Inc. GILD | 6 | $201 |
| Novo Nordisk Inc NVO | 3 | $184 |
| Celltrion USA Inc. 068270.KS | 6 | $132 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.